Psyence Biomedical Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Selling, General & Admin	4.77	3.32	1.8	1.63	1.72
Research & Development	1.47	0.34	0.95	1.61	0.14
Operating Expenses	6.24	3.66	2.75	3.23	1.86
Operating Income	-6.24	-3.66	-2.75	-3.23	-1.86
Interest Expense	-0.01	-0.01	-0.05	-	-
Interest & Investment Income	0.26	0.1	0	0	-
Earnings From Equity Investments	-0.05	-	-	-	-
Currency Exchange Gain (Loss)	-0	-0.01	-0	0.03	-0
Other Non Operating Income (Expenses)	-1.33	0.51	0.57	-	-
EBT Excluding Unusual Items	-7.36	-3.07	-2.23	-3.21	-1.86
Gain (Loss) on Sale of Investments	0.43	0.02	-	-	-
Other Unusual Items	-	4.06	-48.93	-	-
Pretax Income	-6.94	1.01	-51.16	-3.21	-1.86
Net Income	-6.94	1.01	-51.16	-3.21	-1.86
Net Income to Common	-6.94	1.01	-51.16	-3.21	-1.86
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	1	0	-	-	-
Shares Outstanding (Diluted)	1	0	-	-	-
Shares Change	1688.07%	-	-	-	-
EPS (Basic)	-12.56	32.76	-	-	-
EPS (Diluted)	-12.56	32.76	-	-	-
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Free Cash Flow	-8.14	-3.74	-2.95	-1.59	-1.4
Free Cash Flow Per Share	-14.74	-121.22	-	-	-
EBITDA	-6.23	-3.66	-2.75	-	-
D&A For EBITDA	0.01	0	0	-	-
EBIT	-6.24	-3.66	-2.75	-3.23	-1.86

SEC Filings: 10-K · 10-Q